{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Stable+Illness",
    "query": {
      "condition": "Chronic Stable Illness"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T05:18:28.020Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01091246",
      "title": "A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy or Stable Chronic Illness"
      ],
      "interventions": [
        {
          "name": "Q/LAIV (MEDI3250)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FluMist/B/Yamagata",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FluMist/B/Victoria",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 2312,
      "start_date": "2010-03",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2011-09-26",
      "last_synced_at": "2026-07-24T05:18:28.020Z",
      "location_count": 110,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 95 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01091246"
    },
    {
      "nct_id": "NCT04519437",
      "title": "Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Chronic Stable Illness"
      ],
      "interventions": [
        {
          "name": "REGN10933+REGN10987",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 974,
      "start_date": "2020-07-26",
      "completion_date": "2021-11-22",
      "has_results": false,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-07-24T05:18:28.020Z",
      "location_count": 7,
      "location_summary": "Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04519437"
    },
    {
      "nct_id": "NCT04852978",
      "title": "COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy",
        "Chronic Stable Illness"
      ],
      "interventions": [
        {
          "name": "casirivimab+imdevimab",
          "type": "DRUG"
        },
        {
          "name": "Moderna mRNA-1273 vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 295,
      "start_date": "2021-04-29",
      "completion_date": "2022-11-21",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-07-24T05:18:28.020Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Hialeah, Florida + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04852978"
    },
    {
      "nct_id": "NCT05181683",
      "title": "COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Chronic Stable Illness"
      ],
      "interventions": [
        {
          "name": "Casirivimab+Imdevimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2022-01-07",
      "completion_date": "2022-06-03",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-07-24T05:18:28.020Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Winter Park, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05181683"
    }
  ]
}